➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Harvard Business School
Moodys
Johnson and Johnson
Mallinckrodt

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PROMETRIUM

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Prometrium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00152438 ↗ Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone Unknown status University of British Columbia Phase 2 2005-09-01 The primary purpose of this study is to determine the effects of a full dose (300 mg at hs) of oral micronized progesterone (OMP) on vasomotor symptoms [VMS] (hot flushes/night sweats), on forearm blood flow and on lipid levels and blood pressure in menopausal women without cardiovascular disease and with moderate to severe VMS. The hypotheses are that progesterone will improve hot flushes, increase endothelium-dependent forearm blood flow and will decrease blood pressure without change in lipid levels.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Albert Einstein College of Medicine of Yeshiva University Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Brigham and Women's Hospital Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Columbia University Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Mayo Clinic Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status University of California, San Francisco Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status University of Utah Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Prometrium

Condition Name

Condition Name for Prometrium
Intervention Trials
Menopause 3
Suicidal Ideation 3
Infertility 2
Preterm Birth 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Prometrium
Intervention Trials
Amenorrhea 4
Premature Birth 3
Suicidal Ideation 3
Marijuana Abuse 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Prometrium

Trials by Country

Trials by Country for Prometrium
Location Trials
United States 49
Canada 3
Australia 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Prometrium
Location Trials
California 6
North Carolina 5
Washington 3
Massachusetts 3
Connecticut 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Prometrium

Clinical Trial Phase

Clinical Trial Phase for Prometrium
Clinical Trial Phase Trials
Phase 4 8
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Prometrium
Clinical Trial Phase Trials
Not yet recruiting 10
Recruiting 7
Completed 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Prometrium

Sponsor Name

Sponsor Name for Prometrium
Sponsor Trials
National Institute of Mental Health (NIMH) 3
National Institutes of Health (NIH) 3
University of North Carolina, Chapel Hill 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Prometrium
Sponsor Trials
Other 41
NIH 9
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.